MTH-68/H oncolytic viral treatment in human high-grade gliomas

J Neurooncol. Mar-Apr 2004;67(1-2):83-93. doi: 10.1023/b:neon.0000021735.85511.05.

Abstract

Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life, Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.

MeSH terms

  • Brain Neoplasms / mortality
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy*
  • Child
  • Female
  • Glioma / mortality
  • Glioma / pathology
  • Glioma / therapy*
  • Humans
  • Infant
  • Injections, Intravenous
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Newcastle disease virus / immunology*
  • Quality of Life
  • Viral Vaccines / therapeutic use*

Substances

  • Newcastle disease virus vaccine MTH-68-H
  • Viral Vaccines